KYONGBO PHARMACEUTICAL CO., LTD. Logo

KYONGBO PHARMACEUTICAL CO., LTD.

Manufactures APIs and finished drugs, offering global CDMO services from development to production.

214390 | KO

Overview

Corporate Details

ISIN(s):
KR7214390007
LEI:
Country:
South Korea
Address:
충청남도 아산시 실옥로 174, 아산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyongbo Pharmaceutical Co., Ltd., established in 1987, is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company's portfolio includes general APIs, sterile APIs for cephalosporin and carbapenem injectables, and high-potency APIs for anticancer treatments. It also manufactures finished dosage forms, including solid oral drugs and sterile injectables. In addition to its own product lines, Kyongbo operates as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from early-stage development through commercial cGMP production for a global client base. The company leverages its extensive experience and dedicated research facilities to innovate within the pharma-chemical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 50.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 115.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1021.1 KB
2025-07-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.0 KB
2025-07-25 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-09 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.0 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-02 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 34.7 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 108.5 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-18 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.4 KB
2025-06-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-06-17 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 35.5 KB

Automate Your Workflow. Get a real-time feed of all KYONGBO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYONGBO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYONGBO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.